Pacemaker Recommendation for a 71-Year-Old Patient with a Leadless Pacemaker Approaching End of Battery Life

For a 71-year-old healthy patient with a unicameral leadless pacemaker nearing battery depletion, the decision between a bicameral leadless pacemaker (with removal of the existing device) and transvenous conduction system pacing (CSP) involves a careful weighing of several factors. Both options represent advanced and viable solutions, with the "best" choice being highly individualized and requiring detailed clinical assessment.

I. Bicameral Leadless Pacemaker (with potential removal of existing device)

Technology:

• Dual-chamber leadless pacemakers (e.g., Abbott's Aveir DR) are a newer advancement, offering AV synchrony without transvenous leads. They typically consist of two separate leadless devices, one implanted in the atrium and one in the ventricle, communicating wirelessly.

Advantages:

• Eliminates leads and pocket: This is the primary benefit, reducing risks of lead-related complications (fracture, dislodgement, infection) and pocket-related complications (hematoma, erosion, infection).
• Less invasive procedure: Still delivered via a catheter, avoiding a surgical incision in the chest.
• MRI compatibility: Generally MRI conditional.
• Cosmetic appeal: No visible bulge.

Disadvantages:

• Removal of existing leadless pacemaker: While technically possible, retrieval can be challenging, especially for well-encapsulated devices. Risks include cardiac perforation or damage to heart structures. Often, the general approach is to abandon the old device and implant a new one alongside it if safe and feasible, but this depends on the specific device and its position.
• Multiple devices: If the old device is abandoned, having two leadless devices in the right ventricle could raise concerns about hemodynamic impact or interference, though current research suggests it's generally safe for up to two devices. Long-term data on multiple abandoned devices is still accumulating.
• Cost: Newer technologies often come with a higher cost.
• Limited long-term data on dual-chamber leadless: As a newer technology, long-term outcomes and durability are still being established compared to traditional transvenous systems.

II. Transvenous Conduction System Pacing (CSP)

Technology:

• CSP (including His-bundle pacing and left bundle branch area pacing) involves implanting a lead directly into or near the heart's natural conduction system (His bundle or left bundle branch).

Advantages:

• Physiological pacing: CSP aims to restore or preserve the heart's natural electrical activation sequence, potentially leading to better ventricular synchrony, improved left ventricular function, and a reduced risk of pacing-induced cardiomyopathy compared to traditional right ventricular apical pacing.
• Established technology: Transvenous leads and pacemakers have a long history of clinical use and robust long-term data.
• Bicameral capability: Easily provides dual-chamber pacing (atrial and ventricular) if needed.
• No existing device to remove: The existing leadless pacemaker would likely be deactivated and left in place, as it's not a transvenous lead system.

Disadvantages:

• Presence of leads and pocket: This reintroduces the risks associated with traditional transvenous systems, such as lead fracture, dislodgement, infection, and venous occlusion.
• Technical challenges of implantation: CSP can be technically demanding, requiring specialized operator expertise, and may have higher capture thresholds or lead dislodgement risks in some cases, especially with His-bundle pacing. Left bundle branch area pacing has shown more stable thresholds and easier implantation in some studies.
• Battery life: While comparable to leadless pacemakers, transvenous pacemaker batteries also have a finite lifespan, and future battery changes would involve a pocket revision procedure.

Recommendation Considerations for the Patient:

Given the patient's age (71, healthy) and current unicameral leadless pacemaker, here's a balanced perspective:

1. Patient's underlying rhythm and pacing dependency: What is the specific indication for pacing? If only ventricular pacing is needed (e.g., permanent AF with bradycardia), a single-chamber leadless system was appropriate. If there's now a need for AV synchrony (e.g., sick sinus syndrome, AV block), a dual-chamber solution is necessary.
2. Reason for the initial leadless pacemaker: Was it due to venous access issues, high infection risk, or patient preference? These factors might influence the choice moving forward.
3. Risk tolerance and invasiveness:
   • Bicameral Leadless: If the patient strongly desires to avoid leads and a chest pocket, and the existing leadless pacemaker can be safely abandoned or easily retrieved, the new dual-chamber leadless system is an attractive option. However, the potential for a difficult or complicated removal of the existing leadless device needs careful discussion. Many centers opt to abandon a non-functional leadless pacemaker rather than attempting high-risk extraction, especially if it's well-embedded.
   • Transvenous CSP: If physiological pacing is prioritized for long-term cardiac health, or if there are concerns about safely managing the existing leadless device, CSP is a strong contender. While it introduces leads, the benefit of physiological pacing could outweigh the lead-related risks for this healthy individual.

Overall Recommendation (requires more clinical details):

For a 71-year-old healthy patient who likely has an active lifestyle, the goal is to provide reliable pacing with the lowest long-term complication risk and the best physiological outcome.

• If the primary need is dual-chamber pacing with strong emphasis on avoiding transvenous leads and a pocket, and the existing leadless device can be safely managed (either abandoned without issue or easily retrieved), then a bicameral leadless pacemaker system would be a very modern and appealing option. The decision to remove or abandon the old device would depend on expert assessment during the procedure.
• If the primary concern is optimizing physiological ventricular activation to prevent pacing-induced cardiomyopathy and ensure long-term heart health, even with the presence of leads, then transvenous conduction system pacing (CSP) would be highly recommended. This would involve implanting a new transvenous system and deactivating the old leadless pacemaker.

Crucially, this decision should be made in consultation with an experienced electrophysiologist, considering:

• The patient's specific cardiac condition and pacing needs.
• The feasibility and safety of removing the existing leadless pacemaker.
• The patient's preferences and priorities (e.g., desire to avoid leads vs. optimizing physiological pacing).
• The expertise of the implanting center with both bicameral leadless systems and CSP.